Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis: Recent Updates


In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS. [LISTEN TIME: 48 minutes]

To watch the video series component of this episode, click here.

2:09 Early intervention with high-efficacy DMTs in MS

4:26 Anti-CD20 antibodies in MS

8:26 B-cell therapies in MS

10:17 Choosing among different anti-CD20 therapies

13:50 Ublituximab and ULTIMATE I, II trials

22:22 Ublituximab in treatment naïve patients

23:16 Ublituximab in patients with highly active MS

25:45 Bridging the gap between immunology and clinical presentation of MS

28:43 Epstein Barr virus (EBV) and MS

44:46 Addressing patient concerns about EBV and MS

Related Videos
© 2023 MJH Life Sciences

All rights reserved.